Recent Finacing
Recent Raise
EdiGene develops proprietary genome‑editing platforms—including ex vivo HSC/T‑cell editing, in vivo RNA base editing, allogeneic CAR‑T programs and high‑throughput screening—and operates R&D and GMP facilities in China and Cambridge, MA.
